GH Research (NASDAQ:GHRS) Sees Large Volume Increase – What’s Next?

GH Research PLC (NASDAQ:GHRS) shares saw unusually-strong trading volume on Thursday . Approximately 1,155,827 shares changed hands during trading, an increase of 255% from the previous session’s volume of 325,317 shares.The stock last traded at $13.6350 and had previously closed at $15.00.

Analyst Ratings Changes

A number of equities research analysts have commented on GHRS shares. HC Wainwright decreased their price objective on GH Research from $40.00 to $35.00 and set a “buy” rating for the company in a research report on Monday. Needham & Company LLC initiated coverage on GH Research in a report on Monday, October 13th. They set a “buy” rating and a $19.00 price objective for the company. Wall Street Zen downgraded GH Research from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Zacks Research cut shares of GH Research from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a research note on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, GH Research has a consensus rating of “Moderate Buy” and a consensus target price of $29.75.

GH Research Trading Down 7.7%

The firm’s fifty day moving average price is $13.48 and its 200-day moving average price is $13.12. The company has a market cap of $720.36 million, a P/E ratio of -18.71 and a beta of 0.97.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.23) EPS for the quarter, meeting the consensus estimate of ($0.23). As a group, research analysts forecast that GH Research PLC will post -0.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GH Research

A number of institutional investors and hedge funds have recently made changes to their positions in GHRS. Alyeska Investment Group L.P. bought a new position in GH Research in the first quarter valued at approximately $5,018,000. Cormorant Asset Management LP raised its stake in shares of GH Research by 238.8% during the 1st quarter. Cormorant Asset Management LP now owns 2,009,482 shares of the company’s stock worth $22,165,000 after purchasing an additional 1,416,439 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in GH Research in the 1st quarter valued at about $8,272,000. AdvisorShares Investments LLC boosted its stake in shares of GH Research by 15.0% during the 2nd quarter. AdvisorShares Investments LLC now owns 38,256 shares of the company’s stock worth $466,000 after acquiring an additional 5,000 shares during the period. Finally, Troluce Capital Advisors LLC bought a new position in GH Research during the first quarter worth about $1,716,000. Institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).